Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ATG-037 |
| Synonyms | |
| Therapy Description |
ATG-037 is a small molecule inhibitor of CD73, which may block AMP degradation and potentially lead to reactivation of T-lymphocytes under AMP-mediated immunosuppression (Cancer Res 2022;82(12_Suppl):Abstract nr 2576). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ATG-037 | ATG037|ATG 037|CB-708|CB708|CB 708 | ATG-037 is a small molecule inhibitor of CD73, which may block AMP degradation and potentially lead to reactivation of T-lymphocytes under AMP-mediated immunosuppression (Cancer Res 2022;82(12_Suppl):Abstract nr 2576). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05205109 | Phase I | ATG-037 ATG-037 + Pembrolizumab | A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | AUS | 1 |